Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Non Operating Income (2022 - 2026)

Phathom Pharmaceuticals has reported Other Non Operating Income over the past 5 years, most recently at -$831000.0 for Q1 2026.

  • Quarterly Other Non Operating Income fell 3677.27% to -$831000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$998000.0 through Mar 2026, down 7776.92% year-over-year, with the annual reading at -$190000.0 for FY2025, 2275.0% down from the prior year.
  • Other Non Operating Income was -$831000.0 for Q1 2026 at Phathom Pharmaceuticals, down from -$5000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $49000.0 in Q4 2024 and troughed at -$831000.0 in Q1 2026.
  • The 5-year median for Other Non Operating Income is -$8000.0 (2024), against an average of -$78000.0.
  • Year-over-year, Other Non Operating Income surged 450.0% in 2024 and then tumbled 3677.27% in 2026.
  • A 5-year view of Other Non Operating Income shows it stood at -$90000.0 in 2022, then soared by 84.44% to -$14000.0 in 2023, then surged by 450.0% to $49000.0 in 2024, then plummeted by 110.2% to -$5000.0 in 2025, then plummeted by 16520.0% to -$831000.0 in 2026.
  • Per Business Quant, the three most recent readings for PHAT's Other Non Operating Income are -$831000.0 (Q1 2026), -$5000.0 (Q4 2025), and -$7000.0 (Q3 2025).